Your browser doesn't support javascript.
loading
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski, Kiran; Trotti, Lynn Marie; Kotagal, Suresh; Robert Auger, R; Swick, Todd J; Rowley, James A; Hashmi, Sarah D; Watson, Nathaniel F.
Afiliação
  • Maski K; Department of Neurology, Boston Children's Hospital, Boston, Massachusetts.
  • Trotti LM; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.
  • Kotagal S; Department of Neurology, Mayo Clinic, Rochester, Minnesota.
  • Robert Auger R; Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Swick TJ; Neuroscience's Clinical Division, Takeda Pharmaceuticals.
  • Rowley JA; Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan.
  • Hashmi SD; American Academy of Sleep Medicine, Darien, Illinois.
  • Watson NF; Department of Neurology, University of Washington School of Medicine, Seattle, Washington.
J Clin Sleep Med ; 17(9): 1895-1945, 2021 09 01.
Article em En | MEDLINE | ID: mdl-34743790
ABSTRACT

INTRODUCTION:

This systematic review provides supporting evidence for the accompanying clinical practice guideline on the treatment of central disorders of hypersomnolence in adults and children. The review focuses on prescription medications with U.S. Food & Drug Administration approval and nonpharmacologic interventions studied for the treatment of symptoms caused by central disorders of hypersomnolence.

METHODS:

The American Academy of Sleep Medicine commissioned a task force of experts in sleep medicine to perform a systematic review. Randomized controlled trials and observational studies addressing pharmacological and nonpharmacological interventions for central disorders of hypersomnolence were identified. Statistical analyses were performed to determine the clinical significance of all outcomes. Finally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process was used to assess the evidence for the purpose of making specific treatment recommendations.

RESULTS:

The literature search identified 678 studies; 144 met the inclusion criteria and 108 provided data suitable for statistical analyses. Evidence for the following interventions is presented armodafinil, clarithromycin, clomipramine, dextroamphetamine, flumazenil, intravenous immune globulin (IVIG), light therapy, lithium, l-carnitine, liraglutide, methylphenidate, methylprednisolone, modafinil, naps, pitolisant, selegiline, sodium oxybate, solriamfetol, and triazolam. The task force provided a detailed summary of the evidence along with the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations. CITATION Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9)1895-1945.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxibato de Sódio / Distúrbios do Sono por Sonolência Excessiva Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Adult / Child / Humans País/Região como assunto: America do norte Idioma: En Revista: J Clin Sleep Med Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxibato de Sódio / Distúrbios do Sono por Sonolência Excessiva Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Adult / Child / Humans País/Região como assunto: America do norte Idioma: En Revista: J Clin Sleep Med Ano de publicação: 2021 Tipo de documento: Article